Table 1 Clinical and histological features of the study population
Characteristics | First line (n = 4) | Second line (n = 20) | Third line (n = 1) | Fourth line and beyond (n = 16) | Total (n = 51) |
|---|---|---|---|---|---|
Sex | |||||
F | 4 (100%) | 20 (100%) | 11 (100%) | 16 (100%) | 51 (100%) |
M | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Age of onset of cancer (median) | 56.9 years | 52.4 years | 50 years | 52.9 years | 52.9 years |
Metastatic from the outset | |||||
Yes | 0 (0%) | 4 (20%) | 3 (27%) | 9 (56%) | 16 (31%) |
No | 4 (100%) | 16 (80%) | 8 (73%) | 7 (44%) | 35 (69%) |
Age of onset of advanced disease | 69 years | 61 years | 50 years | 53 years | 56 years |
Death (median age) | |||||
Yes | 2 (50%)(72.9 years) | 9 (45%)(64.9 years) | 3 (27%)(47.4 years) | 7 (44%)(63.7 years) | 21 (41%)(64.9 years) |
No | 2 (50%) | 11 (55%) | 8 (73%) | 9 (56%) | 30 (59%) |
Histology | |||||
Ductal | 3 (75%) | 18 (90%) | 11 (100%) | 16 (100%) | 48 (94%) |
Lobular | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Mixed (ductal and lobular) | 1 (25%) | 1 (5%) | 0 (0%) | 0 (0%) | 2 (4%) |
ND | 0 (0%) | 1 (5%) | 0 (0%) | 0 (0%) | 1 (2%) |
Grade | |||||
I | 1 (25%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) |
II | 2 (50%) | 6 (30%) | 8 (73%) | 5 (31%) | 21 (41%) |
III | 1 (25%) | 9 (45%) | 1 (9%) | 10 (63%) | 21 (41%) |
II-III | 0 (0%) | 2 (10%) | 0 (0%) | 1 (6%) | 3 (6%) |
ND | 0 (0%) | 3 (15%) | 2 (18%) | 0 (0%) | 5 (10%) |
ER, PRa | |||||
+/+ | 2 (50%) | 5 (25%) | 5 (45%) | 10 (62%) | 22 (43%) |
−/− | 2 (50%) | 9 (45%) | 2 (18%) | 2 (12%) | 15 (29%) |
Other = +/−, −/+ | 0 (0%) | 5 (25%) | 4 (36%) | 4 (25%) | 13 (25%) |
ND | 0 (0%) | 1 (5%) | 0 (0%) | 0 (0%) | 1 (2%) |
Visceral metastases at diagnostic of advanced disease | |||||
+ | 1 (25%) | 15 (75%) | 9 (82%) | 11 (69%) | 36 (71%) |
- | 3 (75%) | 5 (25%) | 2 (18%) | 5 (31%) | 15 (29%) |
SNC metastasis at diagnostic of advanced disease | |||||
+ | 0 (0%) | 5 (25%) | 2 (18%) | 0 (0%) | 7 (14%) |
- | 4 (100%) | 15 (75%) | 9 (82%) | 16 (100%) | 44 (86%) |
Pretreatment by taxane-trastuzumab-pertuzumab | |||||
+ | 0 (0%) | 14 (70%) | 2 (18%) | 1 (6%) | 17 (33%) |
- | 4 (100%) | 6 (30%) | 9 (82%) | 15 (93%) | 34 (67%) |
Pretreatment by capecitabine-lapatinib | |||||
+ | 0 (0%) | 2 (10%) | 5 (45%) | 5 (31%) | 12 (24%) |
- | 4 (100%) | 18 (90%) | 6 (55%) | 11 (69%) | 39 (76%) |